Prescription Drug Febuxostat Recalled Due to Manufacturing Practice Violations
Amerisource Health Services LLC is recalling approximately 1,932 cartons of Febuxostat (40 mg tablets) nationwide due to deviations from current good manufacturing practices. The firm initiated the recall voluntarily on January 25, 2024.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II, firm-initiated voluntary recall with no reported illnesses or injuries. CGMP deviations relate to manufacturing standards and quality control, making this a precautionary recall with theoretical rather than confirmed harm.
Plain-English summary
The recall affects approximately 1,932 cartons of Febuxostat 40 mg tablets distributed nationwide. The affected product is identified by lot numbers 1015033 (expiration 06/30/2025) and 1016409 (expiration 08/31/2025), distributed by American Health Packaging in Columbus, Ohio.
The U.S. Food and Drug Administration classified this as a Class II recall due to current good manufacturing practice (CGMP) deviations at Amerisource Health Services LLC, the recalling firm. CGMP deviations indicate violations of manufacturing standards and quality control procedures required for pharmaceutical production.
Patients who have received affected cartons should consult with their pharmacy or healthcare provider regarding their medication. The recall was initiated voluntarily by the firm on January 25, 2024, and was classified by the FDA on February 6, 2024.
The recalled product
- Product
- FEBUXOSTAT (FEBUXOSTAT)
- Brand
- FEBUXOSTAT
- Manufacturer
- Amerisource Health Services LLC
- Category
- Drug
- Hazard
- Affected units
- 1,932
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # 1015033
- exp. 06/30/2025
- 1016409
- exp. 08/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · FEBUXOSTAT
- ModerateFebuxostat tablets recalled due to microbial contamination in manufacturing
FDA (Drugs) · 2024-03-20
- HighPrescription drug Febuxostat recalled due to manufacturing contamination
FDA (Drugs) · 2024-03-20
- HighFebuxostat 80 mg prescription tablets recalled for manufacturing contamination
FDA (Drugs) · 2024-01-31
- ModerateFebuxostat Prescription Tablets Recalled Nationwide for Manufacturing Contamination
FDA (Drugs) · 2024-01-31
Same manufacturer · Amerisource Health Services LLC
See all →- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighOxycodone blister cards recalled over seals that let tablets fall out
FDA (Drugs) · 2026-02-18
- HighUnit dose prazosin 2 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same hazard · cgmp deviation
See all →- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09